Intarcia adds $225 million to its coffers to fund a clinical trial and commercialization of its drug-device combination to treat Type II diabetes.
Intarcia Therapeutics yesterday took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize its the drug-device combination treatment it's developing for Type II diabetes.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1GDjqSP
Cap comentari:
Publica un comentari a l'entrada